Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma.

Marcelo Lima RibeiroDiana Reyes-GarauMeritxell VinyolesNúria Profitós-PelejàJuliana Carvalho SantosMarc ArmengolMiranda Fernandez-SerranoAlícia Sedó MorJoan J Bech-SerraPedro Blecua Eva Musulen Carolina de la TorreHari MiskinManel Esteller Francesc BoschPablo MenéndezEmmanuel NormantGael Roué

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

These data validate phosphoproteomic as a valuable tool for the early detection of response to BTK inhibition in the clinic, and for the determination of drug mechanism of action.

Keyphrases

tyrosine kinase
electronic health record
primary care
solid phase extraction
big data
molecularly imprinted
adverse drug
drug induced
machine learning
high resolution
simultaneous determination
liquid chromatography